Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, was recently approved by the FDA for use in combination with chemotherapies (PLD, paclitaxel, and topotecan) in platinum-resistant advanced ovarian cancer, based on a phase III study that demonstrated an improved progression-free survival31. This evidence concerns the gene VEGFA and ovarian cancer.